PMS-RIVASTIGMINE CAPSULE

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE)

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

N06DA03

INN (আন্তর্জাতিক নাম):

RIVASTIGMINE

ডোজ:

1.5MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

RIVASTIGMINE (RIVASTIGMINE HYDROGEN TARTRATE) 1.5MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

60/100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0140521001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2009-07-20

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
PR
PMS-RIVASTIGMINE
Rivastigmine Hydrogen Tartrate Capsules, House Standard
1.5 mg, 3 mg, 4.5 mg and 6 mg of Rivastigmine
(as Rivastigmine Hydrogen Tartrate)
CHOLINESTESTERASE INHIBITOR
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision :
November 1, 2016
www.pharmascience.com
SUBMISSION CONTROL NO: 199174
_ _
_pms-RIVASTIGMINE Product Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................
4
ADVERSE REACTIONS
.............................................................................................
11
DRUG INTERACTIONS
..............................................................................................
23
DOSAGE AND ADMINISTRATION
..........................................................................
24
OVERDOSAGE
...........................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
......................................................... 27
STORAGE AND STABILITY
......................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 29
PART II: SCIENTIFIC INFORMATION
...........................................................................
31
PHARMACEUTICAL INFORMATION
......................................................................
31
CLINICAL TRIALS
....................................................................................................